Clinical Trial

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will be a multicenter, randomized, double-blinded, placebo-controlled clinical study. It is planned to enroll 120 adult patients with moderate-to-severe Atopic Dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatments are medically inadvisable.
Trial Details
NCT Number NCT07054736
Lead Sponsor Zhejiang Kanova Biopharmaceutical Co., LTD
Conditions Atopic Dermatitis
Enrollment 120 participants
Start Date 2025-08-31
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-08